Thalidomide and dexamethasone combination for refractory multiple myeloma. - Wikidata - wikimedia - TriplyDB

Thalidomide and dexamethasone combination for refractory multiple myeloma.

Thalidomide and dexamethasone combination for refractory multiple myeloma.

http://www.wikidata.org/entity/Q43719056

about

Treatment of relapsed and refractory multiple myeloma Thrombosis in multiple myeloma Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.Treating venous thromboembolism in patients with cancer.A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.Access to thalidomide for the treatment of multiple myeloma in Canada: physician behaviours and ethical implications.Management of thalidomide toxicity.Pharmacotherapy of multiple myeloma: an economic perspective.The use of novel agents in the treatment of relapsed and refractory multiple myeloma Thalidomide: a new anticancer drug?Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.Thalidomide and its derivatives: new promise for multiple myeloma.Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options.Thalidomide for the treatment of multiple myeloma.Thalidomide and immunomodulatory drugs in the treatment of cancer.Targeted therapy in multiple myeloma.Current treatment options for myeloma.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Thalidomide and dexamethasone: therapy for multiple myeloma.Immunomodulatory drugs.A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.Thalidomide in multiple myeloma: past, present and future.New horizons in multiple myeloma therapy.Current status of new drugs for the treatment of patients with multiple myeloma.Investigational treatments for multiple myeloma.The treatment of the elderly multiple myeloma patients.Targeted treatments to improve stem cell outcome: old and new drugs.New therapies in multiple myeloma.Novel anti-myeloma agents and angiogenesis.Review of thalidomide in the treatment of newly diagnosed multiple myeloma.Current trends in multiple myeloma management.Treatment of relapsed and refractory myeloma.A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.

P2860

Q26749180-889E2740-283A-484B-81FA-6F2E8972447F Q28219961-3C0CD56A-6EC5-4478-9BA7-B0F92163F1B2 Q33289791-7F9679DD-4559-4BE0-99DC-0D650A42C025 Q33364235-8403C011-6DD5-4445-A459-E85925994110 Q33376008-E2603AB1-2CE3-4373-8C53-30F6F3C26701 Q33400564-E9FBD87E-2836-47DA-8D14-DC4CE0E8C637 Q33408494-E32C130C-2E93-4666-A80E-7DBB5697DA87 Q33973877-1D565B81-4B64-4C16-AD3B-B3A34293695F Q34035424-1C4C7FF1-0D26-4E78-AED5-4ADD0C152A6D Q34343991-BFA2F44A-6248-4BA8-939F-D8911EC35113 Q35095205-DFC6508F-6553-49A8-B579-507E1990A0ED Q35097319-E7037FB1-016C-46D7-9510-6B3124B393C2 Q35164773-33055BED-DC67-4D50-8E12-DCCD56A85542 Q35175287-04B0F216-9DEF-4963-AA5E-ACD0E0853C66 Q35569462-8AEDC92E-39C8-4845-8F00-01F3988FF5CE Q35678932-93550E3C-E342-4AA6-96DF-4FB7B42078E0 Q35870500-F7B7F0BA-BBC1-4403-9D95-4A8E1BA5720A Q36040871-6541802E-0748-4B9B-9B9B-0F3C99CECABE Q36108614-1D754CAA-966D-407D-AD3B-8AF313563BD6 Q36163971-3F55FDB8-C926-4AA0-AF89-24354B953597 Q36171864-2FCDE65C-6EC2-4200-809E-C0A3B4CBF330 Q36284481-849A8B1F-71E9-4F0B-80F0-3A22409F3F47 Q36321396-18AA0F8A-352C-4259-800C-C12184C5F2B9 Q36381565-A50F8590-B450-4CF3-A1CF-32DD20A426C3 Q36616493-4DA73B3F-1065-4B1F-915D-DFA9B12E5847 Q36636660-B98D8806-52F8-47DC-ABE8-5B48B5674839 Q36649839-1FC7C06D-9195-424C-943D-44949D68CE9F Q36654336-976AA152-0373-40C4-9A45-D884225647B1 Q36799834-84DC9ECB-7423-4E3B-A230-F63717976E41 Q36927960-0DE5A0EB-C28E-4822-8CA4-DD226F19F4CC Q36986576-A5B1D232-B228-4C06-BA56-671789ACB706 Q37132903-ED364CEF-6816-4173-B7B9-0DC481C741CB Q37160347-DCE6503E-61AC-4CFE-84E4-83D176A3E01A Q37183557-BCDB1C1F-2631-46F6-9F63-133AF322EE6D Q37209929-F9F4E93A-4644-49CC-B6E4-8C96B64F4020 Q37219701-CEF49E32-58B6-47CD-BD06-A3FC23D4E029 Q37507513-1B24D918-9889-4D16-A54D-337E2F41DA3D Q37609489-7C0F5F60-D4BA-43A9-9E37-321337483642 Q37761370-0AE19172-D969-4E95-B084-545BBE0AF7C3 Q37831402-A884DD59-CFDF-47A9-B73D-6BFFAEC3AE20

P2860

Thalidomide and dexamethasone combination for refractory multiple myeloma.

http://www.wikidata.org/entity/Q43719056

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Thalidomide and dexamethasone combination for refractory multiple myeloma.

@en

Thalidomide and dexamethasone combination for refractory multiple myeloma.

@nl

type

label

Thalidomide and dexamethasone combination for refractory multiple myeloma.

@en

Thalidomide and dexamethasone combination for refractory multiple myeloma.

@nl

prefLabel

Thalidomide and dexamethasone combination for refractory multiple myeloma.

@en

Thalidomide and dexamethasone combination for refractory multiple myeloma.

@nl

P1433

Q43719056-51D83415-936D-4652-893A-72425098FA13

P1476

Q43719056-C9F385CC-08CD-4AD0-93B2-46B88302C59F

P2093

Q43719056-11A156A8-8313-4232-A148-C963AFB28E07

Q43719056-2A177E40-EC8A-4FB3-BD9B-750785E09896

Q43719056-31BE526F-D72E-430F-BADB-09529F0619BC

Q43719056-55C3DCB7-2A09-4E2E-92A5-BAF2B995E5F0

Q43719056-77A7BCAD-5C3A-4757-8FAB-B85A25FC0AD1

Q43719056-86C8A5A5-3BA2-4F9D-B71C-35AF94332367

Q43719056-92BA959E-1752-4F5D-B0AA-7100C425C383

Q43719056-9EAE1C55-A768-4E8F-83B4-415A99FC7FDF

Q43719056-A6FB51C4-F20B-4ADA-BE39-FA075C0E4D8E

Q43719056-A893B320-76BB-49CE-9E01-2FBEC9D9FBB4

P304

Q43719056-AAE7D634-7970-414C-874B-463BD3E1AAF5

P31

Q43719056-D8D14987-9FB2-4B4E-A813-DEEF27508481

P356

Q43719056-3930000A-C78A-4C16-AF95-D80AEE8997A4

P433

Q43719056-B8418337-8137-4288-91E0-C9A288F87318

P478

Q43719056-E5CC45ED-6D22-45D4-91C3-BE9EF7E261FC

P50

Q43719056-AB8B869E-E800-4D7E-8C52-DBB985DDE70D

P577

Q43719056-2E9327A2-7E19-4606-A6E2-3EDE2D140D5A

P698

Q43719056-DF6C593C-96E5-46EC-AC79-A9BB95725603

P921

Q43719056-374D5FC6-EC2E-4F24-8BEE-9C36DB97E5C2

Q43719056-E9E9FA60-03E9-4AB1-BD97-FC913CA2FC84

P356

A:1011132808904

P1433

Annals of Oncology

P1476

Thalidomide and dexamethasone combination for refractory multiple myeloma.

@en

P2093

C Kiamouris

http://www.w3.org/2001/XMLSchema#string

C Papadimitriou

http://www.w3.org/2001/XMLSchema#string

D Gika

http://www.w3.org/2001/XMLSchema#string

E Galani

http://www.w3.org/2001/XMLSchema#string

E Samantas

http://www.w3.org/2001/XMLSchema#string

E Vervessou

http://www.w3.org/2001/XMLSchema#string

G Kouvatseas

http://www.w3.org/2001/XMLSchema#string

I Christakis

http://www.w3.org/2001/XMLSchema#string

K Zervas

http://www.w3.org/2001/XMLSchema#string

N Anagnostopoulos

http://www.w3.org/2001/XMLSchema#string

P304

991-995

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1023/A:1011132808904

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

P577

2001-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11521808

http://www.w3.org/2001/XMLSchema#string

P921